We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Pioneering Biofabrication Institute Advances 3D-Printed Tissues

By Daniel Beris
Posted on 13 Dec 2016
Print article
Image: A computer simulation of the Biofabrication Institute (Photo courtesy of QUT).
Image: A computer simulation of the Biofabrication Institute (Photo courtesy of QUT).
The Herston Health Precinct, a health, aged care, residential, and retail precinct under construction in Brisbane (Australia) at a cost of USD 860 million, has announced a new biofabrication institute that will occupy two floors and will be dedicated to imaging, modeling, and manufacturing of three dimensional (3D) printed patient-specific tissues.

The new Herst biofabrication institute will be realized in partnership with the Queensland University of Technology (QUT, Brisbane, Australia) and the Metro North Hospital and Health Service (Brisbane, Australia). The institute, which is scheduled to open in 2017, will be equipped with all necessary tools for tissue engineering, clinical scanning and visualization, 3D modeling and 3D printing, and will also feature educational spaces and innovation hubs.

The focus of the institute, which marks the very first time that a bioprinting lab is co-located with a high-level hospital in Australia, will be to create patient-specific tissues that can be implanted for a number of different treatments, with the ultimate goal of using autologous cells taken from the patient himself, integrated with composite biodegradable and biocompatible materials for implant purposes in order to 3D print the tissues. All materials used are approved by the U.S. Food and Drug Administration (FDA, Silver Spring, MD, USA).

“A lot of the implants we are developing, we can implant into a patient and as the tissue grows back, it is not rejected, the scaffold will resorb over time and the tissue will grow even more and eventually the implant is gone,” said associate professor Mia Woodruff, PhD, of the QUT biofabrication and tissue morphology group. “We don't always have to use metallic implants any more, we can develop really high-spec composite materials that dissolve as the tissue heals. Organ transplant lists are endless at the moment, and we want to be able to help these people.”

“Researchers, scientists, nurses, and doctors will all be working together to deliver the best outcome for patients. Our vision of healthcare is that the biofabrication institute will pave the way for 3D printers to sit in operating theatres, ready to print tissue as needed, in our hospitals of the future,” said Australian Minister for Health Cameron Dick. “This institute, opening in 2017, will catapult Queensland onto the global stage as a leader in medical innovation and technology that will change the face of healthcare.”

Related Links:
Queensland University of Technology
Metro North Hospital and Health Service
U.S. Food and Drug Administration
Gold Member
12-Channel ECG
CM1200B
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Surgeon Stool with Armrests & Backrest
MR4502
New
Digital Radiography System
DigiEye 680

Print article

Channels

Surgical Techniques

view channel
Image: Graphical abstract; Surgical field during endomyocardial biopsy and fluoroscopic images (Photo courtesy of Heart Rhythm, DOI: 10.1016/j.hrthm.2024.10.069)

Novel Method Combining Heart Biopsy and Device Implantation Reduces Complications Risk

Endomyocardial biopsy (EMB) is a crucial diagnostic tool for identifying various cardiac conditions; however, it carries a risk of complications due to its invasive nature. New research has introduced... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.